Comparison of survival outcomes for people with HR+/HER2− metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary
Hope S Rugo, Rachel M Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky · 2026
Read Comparison of survival outcomes for people with HR+/HER2− metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary by Hope S Rugo, Rachel M Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13367087.txt.
Description
Hope Rugo leads a team that gives in 2026 a plain words sum of a chart study that sets three kin breast cancer drugs side by side. Each drug blocks the cell cycle and pairs with a hormone drug as first care for spread ill. No trial has set the three head to head.
Charts from US care sites show no clear gap in time to ill worse or in life span among the three pairs. The sum backs each of the three as a sound first pick for this ill type. Plain words let patients join the pick talk with their care team.
Catalog record
| CREATOR | Hope S Rugo, Rachel M Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5971 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |